5th Annual Conference on Emerged Markets
3rd – 4th April 2024 | 09.00 – 05.30 pm
Hotel Mirador Mumbai

CATALYST
BUSINESS SERVICES

Introduction

Regulatory environments in EMERGED Markets (emerging markets) can vary widely, as each country has its own set of rules, policies, and institutions governing business activities. However, there are some common trends and challenges that businesses often face when dealing with regulatory issues in these markets. The intricacies of certain different expectations of these countries makes it more interesting.

Some of the countries don't really have any patent regimes to be treated as like Europe and the US.

But there are a few countries where patent is important like Mexico Brazil, we know that patent becomes an important aspect in terms of introducing the generic molecule into the market. Pharma manufacturers need to do some IP searches and will need to generate patent reports and patent search reports like the way we it done for US and Europe.

There are quite a few who acknowledge the fact that China is emerging, and China has emerged, and China is being pursued. The approach that China has in terms of differentiating between requirements, product by product.

For one product, they probably must have proved a particular way of doing Dossier and the concept cannot be extended or extrapolated to another product because that product is different.

Topics

- **Significance and importance of patents scenarios and impact on filing**

  Patent Regime - Patent reports & searches like US & EU in emerging markets

  Brazil, Mexico follow patents to introduce generic molecules.
- **Challenges in CIS markets**
- **RA challenges in China Market**
- **New products and Post approval queries in SA**
- **Actd dossier challenges in Latam**
- **Australia & New Zealand**
- **Asia**
- **Middle East**
- **Post Approval Amendments queries by authorities in markets like Brazil, Mexico, Latam**

Leandro Lozano
Senior Consultant and Owner
RegStrat - Regulatory Affairs Consultancy
Former Registry Analyst Consultant
ANVISA

Adriana Martinez
Former Executive Deputy Director of Drugs and Medicines Sub -Director Executive of Drugs and Medicines
COFEPRIS

Ms Mona Gogia
VP RA
Cadila Pharmaceuticals Lttd

Anurag Agrawal
VP RA
J.B..Chemicals & Pharmaceuticals Limited

DDr Asmita Nimkar
Pharma professional

Santosh Kashyap
VP & HEAD RA
Relicare Tech Services

FOR MORE DETAILS CONTACT
BRIAN NUNES | FOUNDER | Catalyst Business Services
M+919321309147 | brian@catalystbusiness.in

Who Should Attend?
Pharma Companies, Pharma Consulting Companies,
Regulatory Software Developers